Drug price structure ires pharmacists

Russell, Judy
January 1996
New Orleans CityBusiness (1994 to 2008);1/8/96, Vol. 16 Issue 27, p6
Reports on the implications of the changes in the drug price structure to pharmacists in New Orleans, Louisiana. Policy being implemented by Blue Cross and Blue Shield; Comments for Mike Slaughter, owner of Majoria Drugs; Efforts being made by several organizations to block the move.


Related Articles

  • The last word. Davis, Donald A. // DCI;Apr94, Vol. 154 Issue 4, p98 

    Reports on the vote to impose price controls to prescription drugs carried out by the House Health Subcommittee. Provision of insurance to cover medical costs; Function of the Drug Payment Review Commission.

  • Let the market decide who gets discounts. Mossinghoff, Gerald J. // Health Systems Review;Jan/Feb95, Vol. 28 Issue 1, p24 

    Comments on marketplace and government pressures on pharmaceutical pricing. Effects of prescription drug discounts on consumers, health care providers and insurers; Health care inflation; Shifts in pharmaceutical decision making in the 1980s; Influence of managed care organizations over...

  • What price breakthrough drugs?  // Drug Topics;7/25/94, Vol. 138 Issue 14, p7 

    Reports that the Office of Technology Assessment, a nonpartisan research arm of the United States Congress, is looking into the affordability of new therapeutic breakthrough drugs. Potential for price competition in the pharmaceutical market.

  • S.D. bill fights discrimination.  // Drug Topics;10/10/94, Vol. 138 Issue 19, p22 

    Reports on the status of legislation on pharmacy preferential pricing in South Dakota.

  • Bill would help end retailing drug-price bias. Meyer, Larry // Crain's Detroit Business;5/13/96, Vol. 12 Issue 20, p7 

    Reports that the Michigan House is considering the possibility of bill HB 4709 `Fairness in Drug Manufacturer Pricing Bill,' that requires drug manufacturers who offer discounts to make it available to community pharmacies. High cost of prescription drugs to community pharmacies.

  • Regulating the price of the UK's drugs: Second thoughts after the government's first report. Earl-Slater, Alan // BMJ: British Medical Journal (International Edition);2/1/97, Vol. 314 Issue 7077, p365 

    Discusses price regulation of drugs in the United Kingdom. Overview of price regulation scheme; Major problems with the regulations; Lack of robust reasoning; Lack of a theoretical and an empirical basis; Lack of transparency; Lack of due process; Lack of impact analysis; Position of the...

  • New 2% solution not going down well with the industry. Conlan, Michael F. // Drug Topics;12/13/93, Vol. 137 Issue 23, p72 

    Reports on the change from 15% to 17% in the rebate off average manufacturers price (AMP) as a condition for companies that wanted their products covered under a new Medicare outpatient drug benefit. Negative reaction from the pharmaceutical industry; Antidiscount requirement; Advisory...

  • New multitier pricing battles. Conlan, Michael // Drug Topics;1/9/95, Vol. 139 Issue 1, p73 

    Reports on the opposition of the US pharmaceutical industry against multitier drug pricing legislation. Enactment of a uniform drug pricing in Maine; Drug pricing measures in other states.

  • Congressman proposes board to review prices. Conlan, Michael F. // Drug Topics;7/22/96, Vol. 140 Issue 14, p67 

    Reports on the proposal of the United States Representative Tim Johnson for a legislative bill that would create a board which would review drug prices. Opposition of the brand name products on the bill; Possible difficulty that might be faced by the bill; Role and authority of the proposed board.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics